Market research estimates approximately 10 million women in the U.S. are distressed ... an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for ...

Sildenafil Cream is a topical formulation designed to increase genital blood flow, enhancing the arousal response in women with FSAD. When will the Phase 3 study of Sildenafil Cream start?

Dare Bioscience (DARE) announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil ...

Sildenafil Cream, a topical cream formula of sildenafil ... Phase 3 clinical study of Sildenafil Cream in premenopausal women with FSAD. This submission is slated for the first quarter of 2025 ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...

DARE), a leader in innovation for the health and wellbeing of women, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today ...

Market research estimates approximately 10 million women in the U.S. are distressed from ... an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for ...

DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA ...